One pivotal trial by Naveen L Pereira et al evaluated the impact of genotype-guided oral P2Y12 inhibitor therapy on ischemic outcomes in patients with CAD who are carriers of CYP2C19 LOF alleles.[12] This study demonstrated that genotype-guided therapy reduced the incidence of ischemic events compared to conventional therapy, highlighting the potential clinical benefits of tailored antiplatelet treatment strategies based on genetic profiles. This evidence concerns the gene CYP2C19 and coronary artery disorder.